ACOG: Water Immersion Not Recommended for Delivery

Share this content:
ACOG: Water Immersion Not Recommended for Delivery
ACOG: Water Immersion Not Recommended for Delivery

TUESDAY, Oct. 25, 2016 (HealthDay News) -- While a birthing pool during the early stages of labor may offer some advantages, women should not deliver their infant in the water, according to a Committee Opinion published in the November issue of Obstetrics & Gynecology.

According to the American College of Obstetricians and Gynecologists' (ACOG) Committee on Obstetric Practice, delivering a baby in the water may lead to serious health problems. They include: increased risk of mother and infant infections; difficulty in the regulation of the baby's body temperature; increased chance of umbilical cord damage; respiratory distress resulting from the baby inhaling tub water; and potential for asphyxia and seizures.

Hospitals and birthing centers that offer water immersion for women in the first stage of labor need to follow certain guidelines to protect the health and safety of the mother and infant, ACOG said. Those measures include: rigorous processes for candidate selection; maintaining and cleaning tubs and immersion pools; following infection control procedures; monitoring pregnant women at appropriate intervals while immersed; and moving women out of the tubs if there are any concerns about the mother or baby.

"Immersion in water during the first stage of labor may offer some benefits: It may shorten labor and is associated with a decreased use of epidurals," committee chairman Joseph Wax, M.D., said in an ACOG news release. "However, it is important to differentiate between laboring in water and delivering in water. There is no evidence to support delivering a baby in water has benefits to the baby."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »